James M. Daly

October 5, 2026

Halozyme Adds Jim Daly to Board Amid Q2 Earnings Review. Halozyme Therapeutics has appointed Jim Daly to its Board of Directors, a move that signals continued focus on governance and long-term strategy. This update arrives alongside a broader market review of the company's Q2 performance relative to other therapeutics firms. The stock is currently trading above its average analyst target price, with recent technical data showing confirmation near key support levels.

October 5, 2026

Cytokinetics Launches ASPEN-HCM Real-World Study. Cytokinetics has initiated the ASPEN-HCM study to evaluate MYQORZO in real-world patients with symptomatic obstructive hypertrophic cardiomyopathy. The company also announced four upcoming presentations at the HFSA Annual Scientific Meeting 2026. These clinical updates provide new data points for investors, while the stock currently trades near its 52-week low.

October 6, 2026

Madrigal Publishes MAESTRO-NASH Secondary Analysis Data. Madrigal Pharmaceuticals has published data from a pre-specified secondary analysis of its Phase 3 MAESTRO-NASH study in the Journal of Hepatology. The analysis evaluates how patients with altered MASH profiles respond to Rezdiffra. This update provides additional clinical context for the drug's performance in specific patient groups.

October 10, 2026

RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates. RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.